News | November 01, 2023
Pfizer posts Q3 loss as Covid-19 revenues shrink
Revenue in the three months ended on Oct. 1 also slipped by 42% to US$ 13.23 billion
Revenue in the three months ended on Oct. 1 also slipped by 42% to US$ 13.23 billion
Sugammadex Injection is indicated for the reversal of neuromuscular blockade induced by rocuronium bromide and vecuronium bromide
KEYTRUDA is the first immunotherapy approved in the EU for the first-line treatment of this patient population
CMOs showed an increasing reluctance to take on debt in 2022
Adding 20,000 liters of installed biologics drug substance manufacturing capacity
GL0034 is a novel, investigational glucagon-like peptide 1 receptor agonist (GLP-1RA) being studied for the treatment of type 2 diabetes and obesity
Sajjan India Limited is looking for expansion, both organically and through acquisitions, to achieve the planned growth
Lantern is receiving an exclusive and worldwide option to license intellectual property from Bielefeld University related to the collaboration and IP generated from the collaboration
The development and deployment of effective vaccines can help to mitigate the impact of pandemics, and we must prioritize research efforts to achieve this objective
The company reported lifetime high EBIDTA of Rs. 250 crores
Subscribe To Our Newsletter & Stay Updated
